Foghorn Therapeutics Inc. (FHTX)
Largest Insider Buys in Sector
FHTX Stock Price History Chart
FHTX Stock Performance
About Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; …
Insider Activity of Foghorn Therapeutics Inc.
Over the last 12 months, insiders at Foghorn Therapeutics Inc. have bought $0 and sold $853,289 worth of Foghorn Therapeutics Inc. stock.
On average, over the past 5 years, insiders at Foghorn Therapeutics Inc. have bought $4.89M and sold $1.71M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $2.4M was made by Flagship Ventures Fund V General Partner LLC (10 percent owner) on 2020‑10‑27.
List of Insider Buy and Sell Transactions, Foghorn Therapeutics Inc.
| 2024-09-23 | Sale | Chief People Officer | 857 0.0017% | $10.17 | $8,716 | -16.74% | ||
| 2024-09-20 | Sale | Chief People Officer | 35,756 0.0649% | $10.04 | $358,990 | -22.12% | ||
| 2024-09-18 | Sale | Chief People Officer | 11,574 0.022% | $10.05 | $116,319 | -18.10% | ||
| 2024-09-17 | Sale | Chief People Officer | 10,272 0.0189% | $10.04 | $103,131 | -19.36% | ||
| 2024-09-16 | Sale | Chief People Officer | 400 0.0008% | $10.00 | $4,000 | -13.17% | ||
| 2024-09-09 | Sale | Chief Scientific Officer | 20,000 0.0366% | $9.50 | $190,000 | -12.81% | ||
| 2024-03-11 | Sale | Chief Strategy/Bus Ops Officer | 11,000 0.0249% | $6.56 | $72,134 | -7.50% | ||
| 2023-08-16 | Sale | Chief Medical Officer | 311,297 0.6823% | $8.25 | $2.57M | -35.39% | ||
| 2020-10-27 | 10 percent owner | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | |||
| 2020-10-27 | 150,000 1.3579% | $16.00 | $2.4M | -20.50% | ||||
| 2020-10-27 | Chief Scientific Officer | 5,500 0.0498% | $16.00 | $88,000 | -20.50% |
Insider Historical Profitability
| Flagship Ventures Fund V General Partner LLC | 10 percent owner | 9330878 16.8644% | $9.23 | 1 | 0 | <0.0001% |
| Abu Dhabi Investment Authority | 1231081 2.225% | $9.23 | 1 | 0 | <0.0001% | |
| DECICCO CARL | Chief Scientific Officer | 258397 0.467% | $9.23 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| Flagship Pioneering | $85.04M | 22.91 | 12.67M | 0% | +$0 | 5.58 | |
| Fidelity Investments | $18.06M | 4.86 | 2.69M | -4.23% | -$797,637.81 | <0.01 | |
| Raymond James Associates | $14.97M | 4.03 | 2.23M | +7.84% | +$1.09M | 0.01 | |
| Euclidean Capital Llc | $10.56M | 2.84 | 1.57M | 0% | +$0 | 1.36 | |
| BlackRock | $8.83M | 2.38 | 1.32M | +0.73% | +$63,765.13 | <0.0001 |